Loading…
Chinese pharma company focused on central-nervous-system (CNS) drugs, including antidepressants and antipsychotics.
Chinese pharma company focused on central-nervous-system (CNS) drugs, including antidepressants and antipsychotics.
Sells prescription drugs for the nervous system through hospitals, where government group-purchasing programmes press prices on older generics. Chinese rules restrict production of many psychotropic and anaesthetic drugs to licensed makers, which limits the number of competitors in parts of its range.
Moat: narrow (regulatory licence, brand). Established CNS drug portfolio and physician relationships in a specialized therapeutic area.
Headquarters: Taizhou, Jiangsu, China · Employees: 6,003
Size Jiangsu Nhwa Pharmaceutical (002262.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $3.47B, the 745th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥22.87 on 6 Nov 2026.
Performance Over six months the shares gained 2.0%, against +2.2% for the median peer and -16.4% for the China market (cap-weighted) — 10th lowest of 20 in its peer set.
Growth Revenue grew 3.2% over the last twelve months (peer median +13.3%); the operating margin is 18.9% (peer median 12.0%).
Valuation It trades at 19.6× forward earnings against a peer median of 19.0× (8th cheapest of 15).
Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -14 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 15.9 points above its cost of capital (5.0% WACC).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥6.22B | CN¥5.85B | CN¥5.63B | CN¥4.99B | CN¥4.25B |
| Revenue growth | — | +4% | +13% | +17% | — |
| Gross profit | CN¥4.38B | CN¥4.04B | CN¥3.99B | CN¥3.53B | CN¥3.16B |
| EBITDA | n/a | CN¥1.36B | CN¥1.45B | CN¥1.24B | CN¥1.05B |
| Net income | CN¥1.10B | CN¥1.06B | CN¥1.14B | CN¥1.04B | CN¥901M |
| Free cash flow | CN¥579M | CN¥687M | CN¥512M | CN¥677M | CN¥566M |
| Capital expenditure | CN¥490M | CN¥437M | CN¥450M | CN¥374M | CN¥328M |
| Total debt | CN¥392M | CN¥448M | CN¥449M | CN¥173M | CN¥122M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Jiangsu Nhwa Pharmaceutical 002262.SZ | $3.47B | +2% | +3% | 19% | 19.6× | -2.2% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $49.7B | -6% | +6% | 27% | 36.4× | 14.9% |
| Luye Pharma 2186.HK | $839M | -36% | +3% | 18% | 8.1× | -10.5% |
| Otsuka Hldgs 4578.T | $38.6B | +2% | +11% | 18% | 16.3× | 0.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002262.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.7% | +2.1% | 9th highest of 21 |
| 6-month return | +2.0% | +2.2% | 10th lowest of 20 |
| Distance from 52-week high | -12.2% | -24.8% | 7th highest of 21 |
| Revenue growth (TTM) | +3.2% | +13.3% | 6th lowest of 19 |
| Operating margin | 18.9% | 12.0% | 7th highest of 18 |
| Forward P/E | 19.6× | 19.0× | 8th cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | -2.2% | 4.6% | 7th least demanding of 15 |
| Growth delivered (Del g) | +12.0% | +6.6% | 6th highest of 15 |
| Hurdle (Req g minus delivered) | -14.1 pp | -11.4 pp | 6th least demanding of 15 |
| ROIC minus cost of capital | +15.9 pp | +6.5 pp | 2nd highest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.47B | +2% | +3% | 19% | 19.6× | -2.2% | +12.0% |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Viking Therapeutics VKTX | United States | $3.42B | -17% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Henlius Biotech 2696.HK | Hong Kong | $3.41B | -37% | +33% | 12% | 23.8× | 15.2% | +61.4% |
| Tarsus Pharmaceuticals TARS | United States | $3.38B | +12% | +86% | -10% | n/a | 31.9% | +159.5% |
| Piramal Pharma PPLPHARMA.NS | India | $3.37B | +30% | +9% | 3% | 159.9× | n/a | n/a |
| Wockhardt WOCKPHARMA.NS | India | $3.35B | +19% | +26% | 13% | n/a | 56.9% | +4.2% |
| Suzhou Zelgen Biopharmaceuticals 688266.SS | China | $3.60B | -13% | +136% | 29% | 43.4× | 20.5% | +98.4% |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.63B | -7% | +27% | 18% | 14.3× | -2.8% | +10.6% |
| China National Medicines 600511.SS | China | $3.31B | +2% | +3% | 4% | 10.7× | -9.8% | +5.4% |
| Organon & OGN | United States | $3.64B | +4% | -3% | 20% | 4.0× | -4.5% | -1.0% |
| ACADIA Pharmaceuticals ACAD | United States | $3.66B | -5% | +12% | 8% | 21.5× | 16.7% | +19.4% |
| China Medical System 0867.HK | Hong Kong | $3.30B | -16% | +15% | 20% | 10.9× | 2.9% | +2.7% |
| Acutaas Chemicals ACUTAAS.NS | India | $3.28B | +39% | +45% | 36% | 61.8× | n/a | n/a |
| Livzon Pharmaceutical 1513.HK | Hong Kong | $3.69B | -11% | -10% | 19% | 11.3× | -7.7% | +2.0% |
| Amylyx Pharmaceuticals AMLX | United States | $3.70B | +97% | +100% | n/a | n/a | n/a | n/a |
| Apeloa Pharmaceutical 000739.SZ | China | $3.73B | +18% | -16% | 10% | 25.1× | 6.3% | +4.5% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.74B | -11% | +8% | 4% | 6.0× | -5.3% | +7.8% |
| Viridian Therapeutics VRDN | United States | $3.23B | +72% | -63% | -1,781% | n/a | n/a | n/a |
| Arcutis Biotherapeutics ARQT | United States | $3.21B | +21% | +76% | 7% | 37.9× | 48.9% | +367.3% |
| Tasly Pharmaceutical 600535.SS | China | $3.20B | -5% | -4% | 19% | 16.5× | -7.6% | -9.6% |